Prevalence and types of persistent dyslipidemia in patients treated with statins

Croatian Medical Journal

Volumn 54, Issue 4, 2013, Pages 339-345

  Reiner, željko ^a   Tedeschi Reiner, Eugenia ^b,c  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROATIA; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROATIA; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES; TRIGLYCERIDES;

EID: 84884930035     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2013.54.339     Document Type: Article

References (32)

1. G off DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi- Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113:647- 56. Medline:16461837 doi:10.1161/CIRCULATIONAHA.105.552737
2. Bergman Markovic B, Vrdoljak D, Kranjcevic K, Vucak J, Kern J, Bielen I, et al. Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. Croat Med J. 2011;52:566-75. Medline:21853552 doi:10.3325/ cmj.2011.52.566
3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818. Medline:21712404 doi:10.1093/eurheartj/ ehr158
4. Reiner Z. Statins in the primary prevention of the cardiovascular disease. Nat Rev Cardiol. 2013;10:453-64. Medline:23736519 doi:10.1038/nrcardio.2013.80
5. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-45. Medline:16875966 doi:10.1016/j.jacc.2006.04.070
6. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90. Medline:22607822
7. G raham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-414. Medline:17726041 doi:10.1093/eurheartj/ehm316
8. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorolo K, Keil U. EUROASPIRE Study Group EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-37. Medline:19287307 doi:10.1097/ HJR.0b013e3283294b1d
9. Reiner Z, Mihatov S, Milicic D, Bergovec M, Planinc D; TASPIC-CRO Study Group Investigators. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehabil. 2006;13:646-54. Medline:16874158 doi:10.1097/01.hjr.0000183910.59741.96
10. Pecin I, Milicic D, Jurin H, Reiner Z. A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease. Coll Antropol. 2012;36:369-73. Medline:22856217
11. S tacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm. 2006;12:745-51. Medline:17249907
12. Alagona P. Beyond LDL cholesterol: the role of elevated triglycerids and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15:S65-73. Medline:19355805
13. Phatak H, Wentworth C, Sazanov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis. 2009;202:225-33. Medline:18457840 doi:10.1016/j.atherosclerosis.2008.03.016
14. G itt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statintreated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19:221-30. Medline:21450578 doi:10.1177/1741826711400545
15. G oodman SG, Langer A, Bastien NR, McPherson R, Francis GA, Genest JJ Jr, et al. Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). Can J Cardiol. 2010;26:e330-5. Medline:21076724 doi:10.1016/S0828-282X(10)70454-2
16. H o KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs. 2006;6:383-91. Medline:17192128 doi:10.2165/00129784-200606060-00005
17. Park JE, Chiang CE, Munawar M, Pham GK, Sukoanthasarn A, Aquino AR, et al. Lipid.lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol. 2012;19:781-94. Medline:21450606 doi:10.1177/1741826710397100
18. G rundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39. Medline:15249516 doi:10.1161/01.CIR.0000133317.49796.0E
19. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, et al. Lipid Treatment Assesment Project 2 Investigators. Lipid treatment assesment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28-34. Medline:19546386 doi:10.1161/CIRCULATIONAHA.108.838466
20. H ermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J, Elisaf M, et al. Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010;26:445-54. Medline:20001658 doi:10.1185/03007990903500565
21. Perk J, De Backer G, Gohlke H, Graham I, Reiner ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012. Eur Heart J. 2012;33:1635-701. Medline:22555213 doi:10.1093/eurheartj/ehs092
22. G itt AK, Junger C, Jannowitz C, Karmann B, Senges J, Bestehorn K. Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clin Res Cardiol. 2011;100:277-87. Medline:20963598 doi:10.1007/s00392-010-0240-9
23. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey. Atherosclerosis. 2010;213:598-603. Medline:20947087 doi:10.1016/j.atherosclerosis.2010.09.014
24. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey. Prev Med. 2010;51:494-6. Medline:20951724 doi:10.1016/j. ypmed.2010.09.015
25. Reiner Z, Sonicki Z, Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat Med J. 2012;53:278-84. Medline:22661142 doi:10.3325/ cmj.2012.53.278
26. S impson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review. J Clin Lipidol. 2010;4:462-71. Medline:21122692 doi:10.1016/j.jacl.2010.08.026
27. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126:357.e7-357.e27. Medline:23507208 doi:10.1016/j.amjmed.2012.09.004
28. Bergman Markovic B, Kranjcevic K, Reiner Z, Milakovic Blazekovic S, Stojanovic Spehar S. Drug therapy of cardiovascular risk factors: Guidelines versus reality in primary health care service. Croat Med J. 2005;46:944-89. Medline:16342354
29. Wiegand P, McCombs JS, Wang JJ. Factors of hyperlipidemia medication adherence in a nationwide health plan. Am J Manag Care. 2012;18:193-9. Medline:22554007
30. Reiner Z. How to improve cardiovascular diseases prevention in Europe? Nutr Metab Cardiovasc Dis. 2009;19:451-4. Medline:19631516 doi:10.1016/j.numecd.2009.06.006
31. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010;24:19-28. Medline:19682080 doi:10.1111/j.1472-8206.2009.00764.x
32. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statintreated patients: clinical update. Nutr Metab Cardiovasc Dis. 2013. Medline:23932901 doi:10.1016/j.numecd.2013.05.002